Inventor · disambiguated record
Zonghai Li
Also filed as: LI ZONGHAI
16 granted patents·31 pending applications·49 citations·filing 2009–2024
90Inventor score
Files withCRAGE MEDICAL CO LTD20CARSGEN THERAPEUTICS CO LTD10CAFA THERAPEUTICS LTD9LI ZONGHAI3CARSGEN LIFE SCIENCES CO LTD2
Top patents by PatentIndex Score
47 records- 0192US11111295B2Antibody for anti-claudin 18A2 and use thereofCAFA THERAPEUTICS LTD·Filed 2017·Granted Sep 7, 2021·7 cites·29 claims
- 0289US8506963B2Anti-EFGRv3 monoclonal antibodyLI ZONGHAI·Filed 2009·Granted Aug 13, 2013·16 cites·9 claims
- 0382US11447570B2Binding unit targeting fibroblast activation protein α and application thereofCRAGE MEDICAL CO LTD·Filed 2018·Granted Sep 20, 2022·2 cites·12 claims
- 0482US10604740B2Nucleic acids encoding chimeric antigen receptor proteins which bind epidermal growth factor receptor and T lymphocyte expressing the proteinCARSGEN THERAPEUTICS LTD·Filed 2014·Granted Mar 31, 2020·5 cites·18 claims
- 0582US10023639B2Multi-functional antibody polypeptide for cryptic epitope of epidermal growth factor receptor and T cell antigenCARSGEN THERAPEUTICS CO LTD·Filed 2013·Granted Jul 17, 2018·6 cites·8 claims
- 0679US10731127B2Chimeric antigen receptors targeting GPC3 and uses thereofCARSGEN THERAPEUTICS LTD·Filed 2014·Granted Aug 4, 2020·3 cites·19 claims
- 0779US8703917B2Epidermal growth factor receptor variants and pharmaceutical compositions thereofLI ZONGHAI·Filed 2011·Granted Apr 22, 2014·3 cites·3 claims
- 0878US9969799B2Anti-human proBDNF monoclonal antibody, and uses thereof in painsSHANGHAI YILE BIOTECHNOLOGY LTD·Filed 2015·Granted May 15, 2018·4 cites·16 claims
- 0976US2025177544A1Method and composition for treating tumorsCRAGE MEDICAL CO LTD·Filed 2024·Application pending·0 cites
- 1073US8796421B2Human epidermal growth factor receptor variant lacking an exonLI ZONGHAI·Filed 2011·Granted Aug 5, 2014·3 cites·8 claims
- 1170US2024269175A1Compositions and methods of cellular immunotherapyCRAGE MEDICAL CO LTD·Filed 2023·Application pending·0 cites
- 1267US12186343B2Method and composition for treating tumorsCRAGE MEDICAL CO LTD·Filed 2019·Granted Jan 7, 2025·0 cites·20 claims
- 1367US11596653B2Compositions and methods of cellular immunotherapyCRAGE MEDICAL CO LTD·Filed 2018·Granted Mar 7, 2023·0 cites·29 claims
- 1467US2022185880A1Antibody for anti-claudin 18a2 and use thereofCAFA THERAPEUTICS LTD·Filed 2021·Application pending·0 cites
- 1566US2025114438A1Method for treating tumor using immune cellCARSGEN THERAPEUTICS CO LTD·Filed 2024·Application pending·0 cites
- 1664US12435119B2Genetically engineered cell and application thereofCRAGE MEDICAL CO LTD·Filed 2019·Granted Oct 7, 2025·0 cites·38 claims
- 1762US2022016166A1T-cell expressing chimeric receptorCAFA THERAPEUTICS LTD·Filed 2019·Application pending·0 cites
- 1862US2022017926A1Method for gene editing of cell on the basis of crispr/cas systemCAFA THERAPEUTICS LTD·Filed 2019·Application pending·0 cites
- 1961US2025121064A1Gprc5d antibody and use thereofCARSGEN LIFE SCIENCES CO LTD·Filed 2023·Application pending·0 cites
- 2060US2024181055A1Cellular immunotherapy useCRAGE MEDICAL CO LTD·Filed 2022·Application pending·0 cites
- 2159US11419895B2Compositions and methods of cellular immunotherapyCRAGE MEDICAL CO LTD·Filed 2018·Granted Aug 23, 2022·0 cites·10 claims
- 2259US2024285761A1Method and composition for treating tumorsCARSGEN THERAPEUTICS CO LTD·Filed 2022·Application pending·0 cites
- 2358US2025269028A1Chimeric polypeptide for regulating cell physiological activityCARSGEN THERAPEUTICS CO LTD·Filed 2022·Application pending·0 cites
- 2458US2024226151A9Cd94 engineered cell and composition thereofCRAGE MEDICAL CO LTD·Filed 2022·Application pending·0 cites
- 2557US2025135001A1Compositions and methods for cellular immunologyCARSGEN LIFE SCIENCES CO LTD·Filed 2023·Application pending·0 cites
- 2656US2023310600A1Engineered cells and method for engineering cellsCRAGE MEDICAL CO LTD·Filed 2021·Application pending·0 cites
- 2755US2023272341A1Multifunctional immune effector cell and use thereofCRAGE MEDICAL CO LTD·Filed 2021·Application pending·0 cites
- 2854US2022325241A1Immune effector cell for co-expressing chemokine receptorCRAGE MEDICAL CO LTD·Filed 2020·Application pending·0 cites
- 2953US2023148586A1Low-temperature storage of biological samplesCRAGE MEDICAL CO LTD·Filed 2021·Application pending·0 cites
- 3053US2023061005A1Anti-claudin 18.2 antibody and use thereofCRAGE MEDICAL CO LTD·Filed 2021·Application pending·0 cites
- 3153US2023158071A1Tumor combined immunotherapyCRAGE MEDICAL CO LTD·Filed 2019·Application pending·0 cites
- 3252US2023143947A1Immune effector cell in which expression is regulated by cytokinesCRAGE MEDICAL CO LTD·Filed 2020·Application pending·0 cites
- 3351US2022033491A1Combination therapy of cldn18 antibody and chemotherapy drugsCAFA THERAPEUTICS LTD·Filed 2019·Application pending·0 cites
- 3451US2022096544A1Chemokine expressing cell and use thereofCAFA THERAPEUTICS LTD·Filed 2019·Application pending·0 cites
- 3550US2022127570A1Immune effector cell and use thereofCAFA THERAPEUTICS LTD·Filed 2019·Application pending·0 cites
- 3650US2021292427A1Method for treating tumor using immune effector cellCAFA THERAPEUTICS LTD·Filed 2019·Application pending·0 cites
- 3749US2022356447A1Cell for resisting transplant reaction and methodCRAGE MEDICAL CO LTD·Filed 2020·Application pending·0 cites
- 3849US2022127372A1Tcr fusion protein and cell expressing tcr fusion proteinCAFA THERAPEUTICS LTD·Filed 2020·Application pending·0 cites
- 3949US2022056408A1Immune effector cell targeting gpc3 and application thereofCARSGEN THERAPEUTICS CO LTD·Filed 2018·Application pending·0 cites
- 4048US2020347410A1Synnotch receptor-regulated expression of il12CARSGEN THERAPEUTICS CO LTD·Filed 2019·Application pending·0 cites
- 4147US2020261502A1Genetically engineered t cell and application thereofCARSGEN THERAPEUTICS CO LTD·Filed 2018·Application pending·0 cites
- 4245US12178786B2Combination of cellular immunotherapyCRAGE MEDICAL CO LTD·Filed 2019·Granted Dec 31, 2024·0 cites·16 claims
- 4345US11299525B2Chimeric antigen receptor-modified immune effector cell carrying PD-L1 blocking agentCRAGE MEDICAL CO LTD·Filed 2016·Granted Apr 12, 2022·0 cites·11 claims
- 4445US2024182920A1Method for transducing cells with viral vectorCARSGEN THERAPEUTICS CO LTD·Filed 2021·Application pending·0 cites
- 4544US11427633B2Anti-CD19 humanized antibody and immune effector cell targeting cd 19CRAGE MEDICAL CO LTD·Filed 2017·Granted Aug 30, 2022·0 cites·28 claims
- 4642US2022152101A1Cellular immunotherapy combinationCARSGEN THERAPEUTICS CO LTD·Filed 2020·Application pending·0 cites
- 4738US2019359989A1Fusion protein and applications thereofCARSGEN THERAPEUTICS CO LTD·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Zonghai Li files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →